Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $242.50 short put and a strike $237.50 long put offers a potential 42.86% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $242.50 by expiration. The full premium credit of $1.50 would be kept by the premium seller. The risk of $3.50 would be incurred if the stock dropped below the $237.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 63.54 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan Plc – Value Analysis (NYSE:AGN) : September 19, 2016
Mon, 19 Sep 2016 15:08:05 GMT
Asanko Gold Announces Encouraging Initial Drill Results From New Exploration Target
Mon, 19 Sep 2016 11:18:02 GMT
noodls – VANCOUVER, BRITISH COLUMBIA-(Marketwired – Sept. 19, 2016) – Highlights: Highly encouraging results from new near-mine exploration target, Akwasiso 10,000 metres of drilling has been completed over 81 …
Trump Means Change Equals Major Inflection Point
Mon, 19 Sep 2016 10:00:52 GMT
Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company's Innovative Eye Care Pipeline
Sat, 17 Sep 2016 09:38:09 GMT
noodls – DUBLIN and ANN ARBOR, Mich., Sept. 6, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company …
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
Sat, 17 Sep 2016 09:38:09 GMT
noodls – DUBLIN and EMERYVILLE, Calif., Aug. 31, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories …
Related Posts
Also on Market Tamer…
Follow Us on Facebook